David Sterman has worked as an investment analyst for nearly two decades. He started his Wall Street career in equity research at Smith Barney, culminating in a position as Senior Analyst covering European banks. While at Smith Barney, he learned of all the tricks used by Wall Street to steer the best advice to their top clients and their own trading desk. David has also served as Managing Editor at TheStreet.com and Director of Research at Individual Investor. In addition, David worked as Director of Research for Jesup & Lamont Securities. David has made numerous media appearances over the years, primarily on CNBC and Bloomberg TV, and has a master's degree in management from Georgia Tech. David Stermanon

Analyst Articles

Considering real estate was at the epicenter of the 2008 financial crisis and continues to hold back the economy, it’s ironic the sector has been one of the best investments of the past few years. I’m referring specifically to the commercial real estate market, which delivered overall… Read More

For the past couple of weeks, I have been closely following the record heat and drought weather conditions across the United States and their possible implications for investors. A June 29 article of mine describes the upside potential in two stocks that will benefit from the heat and drought, Potash… Read More

The BRICs are priced for an economic meltdown… BRIC is a grouping acronym that refers to Brazil, Russia, India and China. These 4 countries represent the largest and most influential economies in the developing world.  In the past 10 years, the BRIC countries have increased their contributions to global economic… Read More

There is one clear risk when looking at companies that may be “in play.” Even when companies are in the acquisition cross-hairs, a huge amount of patience is still required: a company may be actively holding discussions to sell itself, but any actual agreement… Read More

Biotech investing is the most exciting, highest-reward investment an investor can make. Not only is there the potential for huge gains, but the direct involvement with companies that may have a pivotal role in saving lives is icing on the cake for biotech investors.  But as in every investment, high… Read More

The U.S. consumer has been in a funk for several years now. European consumers feel even more pinched. Even the go-go economies of China and Brazil are seeing the signs of weakening consumer sentiment. Still, credit card giants Visa (NYSE: V) and MasterCard (NYSE:… Read More

Unless you have been living off the grid for the past several years, you may have noticed a change in consumer behavior.  Even with the slight improvement in the economic numbers, many consumers remain shell-shocked from the real estate downturn and unemployment situation.  #-ad_banner-#While… Read More